| Not Yet Recruiting | Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpo NCT07068178 | Jing Li | Phase 2 |
| Recruiting | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment NCT04919629 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovar NCT05605535 | CanariaBio Inc. | Phase 2 |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid NCT05074472 | ZielBio, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Active Not Recruiting | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117 | CanariaBio Inc. | Phase 3 |
| Recruiting | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287 | University of Washington | N/A |
| Completed | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (o NCT03648489 | Imperial College London | Phase 2 |
| Completed | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tu NCT02953457 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, NCT02853318 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Withdrawn | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent NCT02627430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovari NCT02179970 | CCTU- Cancer Theme | Phase 1 |
| Terminated | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Ca NCT02101788 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |
| Completed | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity NCT02016833 | PX Biosolutions | — |
| Unknown | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303 | Gynecologic Oncology Group | Phase 3 |
| Completed | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, NCT00888615 | GOG Foundation | Phase 2 |
| Active Not Recruiting | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Canc NCT01116648 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian NCT00262847 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745 | GOG Foundation | Phase 3 |